|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to explore the usefulness of the determination of free light chains (FLC) in serum as a biomarker of flare in patients with systemic lupus erythematosus (SLE) and to analyze the differences in their discriminatory capacity with complement C3 and C4.
|
31773496 |
2020 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Established biomarkers of composite disease activity, SLE-associated antibodies, type I interferon (IFN), and complement C3, correlated with composite SLEDAI, but did not significantly associate with many individual SLE pathologies.
|
31594956 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Multiple logistic regression analysis showed that IL-6, IL-8, and IL-18 significantly increased odds ratio (OR) for active SLE at baseline while complement C3 and IL-18 increased OR for active SLE at 12 weeks.
|
31842967 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
To investigate the diagnostic role of complement C3, complement C4, C-reactive protein (CRP), procalcitonin (PCT), white blood cell count (WBC), neutrophil CD64 (nCD64) index, lymphocyte subsets and their combination in differentiating bacterial infection from disease relapse in systemic lupus erythematosus (SLE).
|
30712491 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The presence of albuminuria, lymphopenia and low complement C3 levels were independent prognostic predictors of short-term mortality in SLE patients with PI.
|
30968568 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
In this study, we investigate the effect of a novel complement C3 inhibitor, CRIg/FH, in the treatment of lupus nephropathy in MRL/lpr lupus mice.
|
31752725 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
The combined diagnosis of SLE with ANA, anti-ds-DNA antibody, complement C3 and C4 can play a complementary role in the diagnosis and treatment of SLE patients, and it is of great significance to the diagnosis and treatment planning of SLE patients.
|
30680018 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The diagnosis of SLE was based on clinical presentations such as myalgia, skin rashes, ulcers, and fatigue along with relevant laboratory findings including positive anti ds-DNA antibody and depressed levels of complement C3 and C4 proteins.
|
29306594 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Higher sSIGLEC-1 concentrations were associated with lower serum complement component 3 and increased frequency of renal complications in European patients, but not with the SLE Disease Activity Index clinical score.
|
30053827 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Regarding clinical features, SLE patients with ulceration had higher GAS5 expression levels in CD4<sup>+</sup> T cells than those without ulceration (P<0.05), and the expression of miR-21 was significantly higher in CD4<sup>+</sup> T cells of SLE patients with low levels of complement component 3 (C3) than in those with normal levels of complement C3 (P<0.05).
|
29387192 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Then miR-29b expression was upregulated in SLE and correlated with SLEDAI score, anti-dsDNA and complement C3 level in patients with SLE.
|
29884225 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Importantly, in patients with SLE(±APS), galectin-9 was also superior to anti-dsDNA antibody (AUC 0.70), or complement C3 (AUC 0.70) and C4 (AUC 0.78) levels in detecting the IFN signature.
|
30185417 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Prospective longitudinal study of IFNα, IFNγ-inducible protein 10 (IP-10) and sialic acid-binding Ig-like lectin 1 (SIGLEC1) vs antibodies against dsDNA (ELISA and Farr radioimmunoassay), dsDNA-complexed nucleosomes (anti-dsDNA-NcX: ELISA), nucleosomes (ANuA: ELISA) and complement C3/C4 for correlation with DA (measured by BILAG 2004 index) in 26 SLE patients (77 visits).
|
28859328 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Moreover, a combination of DKK-1 with anti-dsDNA and/or levels of complement C3 and C4 could not increase the specificity and/or sensitivity for identification of patients with LN diseases, but both ROC curve and multiple-factor nonconditional logistic regression analysis showed that serum DKK-1 was considered better positive biomarker for identification of LN in SLE patients.
|
28373995 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
To investigate the clinical value of anti-Sm antibodies in diagnosis and monitoring of systemic lupus erythematosus (SLE) and their ability to predict lupus flares compared with that of anti-dsDNA antibody and complement (C3) assays.
|
28281463 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Both C3 and C4 showed a high sensitivity (93.3% and 86.7%) to detect CV in SLE at cut-off values below 81.4 mg/dl and 16.8 mg/dl, respectively.
|
29087263 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of complement C3 and C4 proteins, considered as a marker of SLE activity, correlated negatively with proportions of CD3(+)CD4(+) and CD3(+)CD4(-) T cells expressing Tim-3.
|
26076826 |
2015 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
The level of plasma miR-21 was not associated with the level of white blood cells (P = 0.4284), red blood cells (P = 0.4079), and platelets (P = 0.4961), but significantly correlated with the level of plasma complement C3 (r = -0.5297, P = 0.0004), C4 (r = -0.4732, P = 0.0020), and serum uric acid (r = 0.3932, P = 0.0121) in SLE patients.
|
24659142 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The heritability and genetics of complement C3 expression in UK SLE families.
|
19387462 |
2009 |
|
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
LHGDN |
Association of polymorphisms in complement component C3 gene with susceptibility to systemic lupus erythematosus.
|
18174230 |
2008 |
|
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
LHGDN |
Three distinct profiles of serum complement C4 proteins in pediatric systemic lupus erythematosus (SLE) patients: tight associations of complement C4 and C3 protein levels in SLE but not in healthy subjects.
|
16893076 |
2006 |
|
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Complement C3 and C4 levels were consistently normal during flares of her lupus and haemolytic activity of her complement was absent, suggesting a deficiency of an early component of the complement cascade.No C1q could be detected.
|
10735963 |
2000 |
|
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that low levels of CR1 on erythrocytes in SLE patients are required during the course of the disease and that the 6.9 kb restriction fragment does not play a role in causing susceptibility to the disease.
|
8595925 |
1995 |
|
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Not surprisingly, total and partial deficiencies of certain complement components and C3b receptors are associated with rheumatic diseases, particularly systemic lupus erythematosus.
|
1455049 |
1992 |
|
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
On the other hand, CR1 levels of PMN stimulated by FMLP were also found to be decreased in SLE patients, while both the expression of circulating PMN (cells isolated at 4 degrees C) and the total cellular CR1 content were normal.
|
2974768 |
1988 |